SEC Form 4 · accession 0001144204-17-045695
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas T. Thomas
Director
Period of report
Aug 29, 2017
Accepted (ET)
Aug 29, 2017 · 5:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.00 | Aug 29, 2017 | A | 11,667 | A | Aug 29, 2017 | Nov 3, 2021 | Common Stock | 11,667 | 23,334 | D |
Explanation of responses
- F1On November 4, 2016, the reporting person was granted an option to purchase 35,000 shares of common stock of the issuer. The option vests as follows: (i) 11,667 shares vest upon the uplisting of the issuer to the Nasdaq Stock Market, (ii) 11,667 shares vested on December 13, 2016 upon the cumulative funding of the issuer of or in excess of $5,000,000 by institutional investors commencing November 4, 2016 and (iii) 11,666 shares vest upon the first submission of a New Drug Application to the U.S. Food and Drug Administration for one of the issuer's products by either the issuer or an issuer licensee. On August 29, 2017, the performance criteria in subsection (i) was met, resulting in vesting of the option as to 11,667 shares.